746671-17-0Relevant articles and documents
Use of a Conformational-Switching Mechanism to Modulate Exposed Polarity: Discovery of CCR2 Antagonist BMS-741672
Yang, Michael G.,Xiao, Zili,Cherney, Robert J.,Tebben, Andrew J.,Batt, Douglas G.,Brown, Gregory D.,Chen, Jing,Cvijic, Mary Ellen,Dabros, Marta,Duncia, John V.,Galella, Michael,Gardner, Daniel S.,Khandelwal, Purnima,Ko, Soo S.,Malley, Mary F.,Mo, Ruowei,Pang, Jian,Rose, Anne V.,Santella, Joseph B.,Shi, Hong,Srivastava, Anurag,Traeger, Sarah C.,Wang, Bei,Xu, Songmei,Zhao, Rulin,Barrish, Joel C.,Mandlekar, Sandhya,Zhao, Qihong,Carter, Percy H.
, p. 300 - 305 (2019/03/12)
We encountered a dilemma in the course of studying a series of antagonists of the G-protein coupled receptor CC chemokine receptor-2 (CCR2): compounds with polar C3 side chains exhibited good ion channel selectivity but poor oral bioavailability, whereas
CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY
-
Page/Page column 10, (2008/06/13)
This invention relates generally to modulators of chemokine receptor activity having unexpected combination of desirable pharmacological properties. Pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and
Cyclic derivatives as modulators of chemokine receptor activity
-
Page/Page column 37, (2008/06/13)
The present application describes modulators of MCP-1 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the treatment of rheumatoid arthritis, multiple sclerosis, atherosclerosis and asthma.
Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity
-
Page/Page column 32, (2010/02/11)
The present application describes modulators of MCP-1 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma, multiple sclerosis, artherosclerosis, and rheumatoid arthritis.